Treatment options in Waldenström’s macroglobulinaemia: the role of the purine analogues

Bibliography

• WALDENSTROM J: Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia - a new syndrome? Acta Med. Scam/. (1944) 117:216–247.
   Google Scholar
• •This is the original description of WM by Professor Jan Waldenström.
   Google Scholar
• DIMOPOULOS MA, PANAYIOTIDIS P, MOULOPOULOS LA et al: Waldenstrom's macroglobulinemia: clinical features, complications, and management. I Chit. Oncol (2000) 18:214–226.
   PubMed Web of Science ®Google Scholar
• ••This is a comprehensive review of theclinical features and treatment of WM.
   Google Scholar
• OWEN RG, JOHNSON SA, MORGANGJ: Waldenström's macroglobulinaemia: laboratory diagnosis and treatment. Hematol Omni (2000) 18:41–49.
   Google Scholar
• •Another recent review with some discussion of the diagnostic difficulties encountered in WM.
   Google Scholar
• HARRIS NL, JAFFE ES, STEIN H et al: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 84:1361–1392.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997.1 Chit. Omni (1999) 17:3835–3849.
   Google Scholar
• DIMOPOULOS MA, ALEXANIAN R: Waldenström's macroglobulinemia. Blood (1994) 83:1452–1459.
   PubMed Web of Science ®Google Scholar
• HERRINTON LJ, WEISS NS: Incidence of Waldenström's macroglobulinemia. Blood (1993) 82:3148–3150.
   PubMed Web of Science ®Google Scholar
• OWEN RG, BARRANS SL, RICHARDS SJ et al: Waldenström's macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am. 1 Chit. Pathol (In Press).
   Google Scholar
• FACON T, BROUILLARD M, DUHAMEL A et al.: Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. j Chit. Oncol (1993) 11:1553–1558.
   PubMed Web of Science ®Google Scholar
• GOBBI PG, BETTINI R, MONTECUCCO C et al: Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood (1994) 83:2939–2945.
   PubMed Web of Science ®Google Scholar
• MOREL P, MONCONDUIT M, JACOMY J et al: Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood (2000) 96:852–858.
   PubMed Web of Science ®Google Scholar
• GERTZ MA, KYLE RA, NOEL P: Primarysystemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. I Chit. Oncol (1993) 11:914–920.
   PubMed Web of Science ®Google Scholar
• OWEN RG, LUBENKO A, SAVAGE J, PARAPIA LA, JACK AS, MORGAN GJ: Autoimmune thrombocytopenia in Waldenström's macroglobulinemia. Am. Hematol (2001) 66:116–119.
   PubMed Web of Science ®Google Scholar
• DELLAGI K, DUPOUEY P, BROUET JCetal.: Waldenström's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood (1983) 62:280–285.
   Google Scholar
• LATOV N, BRAUN PE, GROSS RB: Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc. Natl. Acad. Li. USA (1981) 78:7139–7142.
   PubMed Web of Science ®Google Scholar
• BARTL R, FRISCH B, MAHL G etal.: Bone marrow histology in Waldenstrom's macroglobulinaemia. Land. I Haematol. (1983) 31:359–375.
   Google Scholar
• THE INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl. I Med. (1993) 329:987–994.
   Google Scholar
• ARMITAGE JO, WEISENBERGER DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. I Chit. Omni (1998) 16:2780–2795.
   Google Scholar
• OWEN RG, PARAPIA LA, HIGGINSON J et al: Clinicopathological correlates of IgM paraproteinemias. CM]. Lymphoma (2000) 1:39–43.
   PubMedGoogle Scholar
• KYLE RA, GARTON JP: The spectrum ofIgM monoclonal gammopathy in 430 cases. Mayo. Chit. Proc. (1987) 62:719–731.
   PubMed Web of Science ®Google Scholar
• REINHART WH, LUTOLF 0, NYDEGGER UR, MAHLER E STRAUB PW: Plasmapheresis for hyperviscosity syndrome in Waldenström's macroglobulinemia and multiple myeloma: influence on blood rheology and the microcirculation. I Lab. Chit. Med. (1992) 119:69–76.
   PubMedGoogle Scholar
• KOENIG W, SUND W LOWEL H et al:Association between plasma viscosity and all cause mortality. Results from the MONICA-Augsburg cohort follow-up study 1984-1992. Br .j Haematol (2000) 109:453–458.
   Google Scholar
• MCCALLISTER BD, BAYRD ED, HARRISON EG, MCGUCKIN WF: Primary macroglobulinemia. Review with a report on thirty-one cases and notes on the value of continuous chlorambucil therapy. Am. I Med. (1966) 43:394–434.
   Google Scholar
• MACKENZIE MR, FUDENBERG HH: Macroglobulinemia: an analysis for forty patients. Blood (1972) 39:874–889.
   PubMed Web of Science ®Google Scholar
• KYLE RA, GRIEPP PR, GERTZ MA et al: Waldenström's macroglobulinaemia: a prospective study comparing daily versus intermittent oral chlorambucil. Br I Haematol (2000) 108:737–742.
   PubMed Web of Science ®Google Scholar
• CASS RIVI, ANDERSON BR, VAUGHAN JH: Waldenstrom's macroglobulinemia with increased serum IgG levels treated with low doses of cyclophosphamide. Ann. Int. Med. (1969) 71:971–977.
   PubMedGoogle Scholar
• PETRUCCI MT, AVVISATI G, TRIBALTO M, GIOVANGROSSI P, MANDELLI F: Waldenström's macroglobulinemia: results of a combined oral treatment in 34 newly diagnosed patients. j Int. Med. (1989) 226:443–447.
   PubMed Web of Science ®Google Scholar
• CASE DC, ERVIN TJ, BOYD MA, REDFIELD DL: Waldenstrom's macroglobulinaemia: long term results with the M2 protocol. Canc. Invest. (1991) 9:1–7.
   PubMed Web of Science ®Google Scholar
• LEBLOND V, CAZIN B, FERMAND JP et al.: Results of a multicentric randomized study comparing the efficacy of cyclophosphamide, doxorubicin and prednisone (CAP) to that of fludarabine (FAMP) in patients with Waldenstrom's macroglobulinemia (WM) in first relapse or primary refractory disease. Ann. Omni (1999) 10\(Suppl. 3):66a.
   Google Scholar
• PLUNKETT W, GANDHI V: Nucleoside analogs: cellular pharmacology, mechanisms of action, and strategies for combination therapy. In: Nucleoside Analogs in Cancer Therapy Cheson BD, Keating MJ, Plunkett W (Eds.), Marcel Dekker (1997):1–36.
   Google Scholar
• KEATING MJ: Clinical trials of the purine analogs in chronic lymphocytic leukemia. In: Nucleoside Analogs in Cancer Therapy. Cheson BD, Keating MJ, Plunkett W (Eds.), Marcel Dekker (1997):201–226.
   Google Scholar
• RAT KR, PETERSON BL, APPLELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl. j. Med. (2000) 343:1750–1757.
   PubMedGoogle Scholar
• THE FRENCH COOPERATIVE GROUP ON CLL: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet (1996) 347:1432–1438.
   PubMed Web of Science ®Google Scholar
• FORAN JM, OSCIER D, ORCHARD J etal.: Pharmacokinetic study of single low doses of oral fludarabine phosphate in patients with 'low grade' non-Hodgkin's Lymphoma and B-cell chronic lymphocytic leukemia. J. Chu. Oricol (1999) 17:1574–1579.
   Google Scholar
• KANTARJIAN HM, ALEXANIAN R, KOLLER CA, KURZROCK R, KEATING M: Fludarabine therapy in macroglobulinemic lymphoma. Blood (1990) 75:1928–1931.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, O'BRIEN S, KANTARJIAN H et al: Fludarabine therapy in Waldenström's macroglobulinemia. Am. j. Med. (1993) 95:49–52.
   PubMed Web of Science ®Google Scholar
• ZINZANI PL, GHERLINZONI BENDANDI M et al: Fludarabine treatment in resistant Waldenström's macroglobulinaemia. Eur. I Haematol. (1995) 54:120–123.
   PubMed Web of Science ®Google Scholar
• LEBLOND V, BEN-OTHMAN T, DECONINCK E etal.: Activity of fludarabine in previously-treated Waldenström's macroglobulinemia: a report of 71 cases. J. Chu. Oricol (1998) 16:2060–2064.
   Google Scholar
• •This is largest study assessing the use of fludarabine in patients with relapsed/ refractory WM.
   Google Scholar
• FORAN JM, ROHATINER AZS, COIFFIER B et al.: Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia and mantle-cell lymphoma. J. Chu. Oricol (1999) 17:546–553.
   PubMedGoogle Scholar
• DHODAPKAR M, JACOBSON J, GERTZ M et al.: Phase II intergroup trial of fludarabine (FAIVIP) in Waldenström's macroglobulinemia (WM): Results of the Southwest Oncology Group trial (SWOG 9003) in 220 patients. Blood (1997) 90\(Suppl. 1):577a.
   Google Scholar
• DHODAPKAR MV, JACOBSON J, GERTZ M et al: Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenström's macroglobulinemia (WM). Blood (1999) 94\(Suppl. 1):705a.
   Google Scholar
• JACOBS A: Cold agglutinin hemolysis responding to fludarabine therapy. Am. Hematol (1996) 53:279–280.
   PubMed Web of Science ®Google Scholar
• TONDINI C, BALZAROTTI M, RAMPINELLI I et al: Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a Phase II randomized study. Ann. amyl (2000) 11:231–233.
   Google Scholar
• ROBAK T, BLONSKI JZ, KASZNICKI Met al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood (2000) 96:2723–2729.
   Google Scholar
• DIMOPOULOS MA, KANTARJIAN H, ESTEY E et al.: Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Int. Med. (1993) 118:195–198.
   PubMed Web of Science ®Google Scholar
• •This is the largest study assessing the efficacy of cladribine in previously treated patients with WM.
   Google Scholar
• DIMOPOULOS MA, KANTARJIAN H, WEBER D et al.: Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. I Chu. Oricol (1994) 12:2694–2698.
   PubMed Web of Science ®Google Scholar
• •This is the largest study assessing the efficacy of cladribine in previously untreated patients.
   Google Scholar
• DIMOPOULOS MA, WEBER DM, KANTARJIAN H, KEATING M, ALEXANAIAN R: 2-Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. Ann. Oricol (1994) 5:288–289.
   PubMed Web of Science ®Google Scholar
• DELANNOY A, VAN DEN ESTE E, MICHAUX JL, BOSLY A, FERRANT A: Cladribine for Waldenström's macroglobulinaemia. Br. I Hematol (1999) 104:935–936.
   PubMedGoogle Scholar
• DIMOPOULOS MA, WEBER D, DELASALLE KB, KEATING M, ALEXANIAN R: Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2- chlorodeoxyadenosine: identification of prognostic factors. Ann. Oricol (1995) 6:49–52.
   PubMed Web of Science ®Google Scholar
• FRIDRIK MA, JAGER G, BALDINGER C, KRIEGER 0, CHOTT A, BETTELHEIM P: First-line treatment of Waldenström's disease with cladribine. Ann. Hematol. (1997) 74:7–10.
   PubMed Web of Science ®Google Scholar
• BETTICHER DC, HSU SCHMITZ SF, RATSCHILLER D etal.: Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Br I Haematol (1997) 99:358–363.
   Google Scholar
• LIU ES, BURIAN C, MILLER WE, SAVEN A: Bolus administration of cladribine in the treatment of Waldenström's macroglobulinaemia. Br I Haematol (1998) 103:690–695.
   PubMed Web of Science ®Google Scholar
• HELLMAN A, LEWANDOWSKI K, ZAUCHA JM, BIENIASZEWSKA M, HALABURDA K, ROBAK T: Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur. I Haematol (1999) 63:35–41.
   PubMedGoogle Scholar
• CHESON BD, GREVER MR: Clinical development of 2'-deoxycoformycin. In: Nucleoside Analogs in Cancer Therapy Cheson BD, Keating MJ, Plunkett W (Eds.), Marcel Dekker (1997):95–122.
   Google Scholar
• RIDDELL S, JOHNSTON JB, RAYNER HL, ISRAELS LG: Response of Waldenström's macroglobulinaemia to pentostatin. Canc. Treat. Rep. (1986) 70:546–548.
   PubMedGoogle Scholar
• BYRD JC, WHITE CA, LINK B etal.: Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann. Oricol. (1999) 10:1525–1527.
   Google Scholar
• FORAN JM, ROHATINER AZS, CUNNINGHAM D et al:European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small 13-cell lymphocytic lymphoma. I Chu. Oricol (2000) 18:317–324.
   PubMed Web of Science ®Google Scholar
• WEBER DM, GAVINO M, HUH Y, CABANILLAS F, ALEXANIAN R: Phenotypic and clinical evidence supports rituximab for Waldenström's macroglobulinemia. B/ood(1999) 94\(Suppl. 1):125a.
   Google Scholar
• DIMOPOULOS MA, KIAMOURIS C, KARKANTARIS C, MITSOULI C, VINIOU N: Prospective evaluation of rituximab for the treatment of Waldenström's macroglobulinemia. Blood (2000) 96\(Suppl. 1):169a.
   Google Scholar
• OSTERBORG A, DYER MJ, BUNJES D et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of Campath-1H Treatment in Chronic Lymphocytic Leukemia. aka (1997) 15:1567–1574.
   Google Scholar
• SALISBURY JR, RAPSON NT, CODD JD, ROGERS MV, NETHERSELL ABW: Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. j Clin. Pathol. (1993) 47:313–317.
   Google Scholar
• DYER MJS, HALE G, MARCUS R, WALDMANN H: Remission induction in patients with lymphoid malignancies using unconjugated campath-1 monoclonal antibodies. Leuk. Lymph. (1990) 2:179–193.
   PubMedGoogle Scholar
• HUH Y, KANTARJAIN H, PIERCE S et al.: Expression of CD52 in human hematopoietic malignancies. Blood (1998) 92\(Suppl. 1):4199a.
   Google Scholar
• HALE G, DYER MJS, CLARK MR et al: Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody campath-1H. Lancet (1988) 2:1394–1399.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, OSTERBORG A, BRITTINGER G et al.: Campath-1H monoclonal antibody therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. I Clin. Oncol. (1998) 16:3257–3263.
   PubMed Web of Science ®Google Scholar
• DESIKAN R, DHODAPKAR M, SIEGEL D etal.: High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br. Haematol (1999) 105:993–996.
   Google Scholar
• DREGER P, GLASS B, KUSE R et al: Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia. Br. I Haematol (1999) 106:115–118.
   PubMed Web of Science ®Google Scholar
• MARTINO R, SHAH A, ROMERO P et al.: Allogeneic bone marrow transplantation for advanced Waldenström's macroglobulinemia. Bone Marrow Transplant. (1999) 23:747–749.
   PubMedGoogle Scholar
• http://www.waldenstroms.org Schering Health Care Ltd.
   Google Scholar